Terje Pedersen More evidence for the benefits of aggressive lipid-lowering with statins has come from the IDEAL study, which randomised nearly 9000 post-MI patients to either 80 mg of atorvastatin or
Terje Pedersen
More evidence for the benefits of aggressive lipid-lowering with statins has come from the IDEAL study, which randomised nearly 9000 post-MI patients to either 80 mg of atorvastatin or 20/40 mg simvastatin daily.Terje Pedersenfrom Ulleval University Hospital in Norway presented the findings.
Related Episodes
Statins and ARBs: a Special Combination?
John McMurray The VALIANT trial compared ACE-inhibitor, ARB and a combination of the two in high-risk post-MI patients, and found there may be an interaction between them and statins. John McMurray fr
17 November 2005
0:00